1. Methylergonovine produces uterotonic activity by acting as a partial agonist at which combination of receptors in myometrial smooth muscle, both of which signal through Gq-coupled phospholipase C activation and intracellular calcium mobilization?
A) Oxytocin receptors and beta-2 adrenergic receptors
B) Alpha-1 adrenergic receptors and 5-HT2A serotonin receptors
C) Dopamine D2 receptors and muscarinic M3 receptors
D) Beta-1 adrenergic receptors and 5-HT1B serotonin receptors
E) Oxytocin receptors and alpha-2 adrenergic receptors
ANSWER: B
Rationale:
Methylergonovine is a partial agonist at both alpha-1 adrenergic receptors (alpha-1 ARs) and 5-HT2A serotonin receptors expressed on myometrial smooth muscle cells. Both receptor subtypes are Gq-coupled and activate phospholipase C (PLC), generating inositol trisphosphate (IP3) — which releases calcium from the sarcoplasmic reticulum — and diacylglycerol (DAG), which activates protein kinase C (PKC). The combined activation of these two pathways produces the sustained tonic myometrial contraction that is the hallmark of ergot uterotonic action.
Option A: Option A is incorrect because beta-2 adrenergic receptors are Gs-coupled and mediate uterine relaxation (tocolysis), not contraction; methylergonovine does not act at beta-2 ARs as part of its uterotonic mechanism.
Option C: Option C is incorrect because dopamine D2 receptors are expressed at the chemoreceptor trigger zone and contribute to the emetic side effects of ergometrine, not to uterotonic activity; muscarinic M3 receptors are not the primary contractile mediators of ergot action in the myometrium.
Option D: Option D is incorrect because beta-1 adrenergic receptors are cardiac receptors, and 5-HT1B receptors mediate cerebrovascular vasoconstriction relevant to antimigraine ergot action, not uterotonic contraction.
Option E: Option E is incorrect because while oxytocin receptors are expressed in the myometrium, methylergonovine does not bind meaningfully to oxytocin receptors; its interaction with the oxytocin receptor system is indirect, through sensitization of downstream signaling rather than direct agonism, and alpha-2 adrenergic receptors inhibit rather than stimulate smooth muscle contraction via Gi coupling.
2. A third-year obstetrics resident asks why methylergonovine cannot be used to augment labor, given that it is a potent uterotonic. Which statement correctly explains the pharmacodynamic basis for this restriction?
A) Methylergonovine has no effect on uterine contractility until after placental delivery because progesterone blocks myometrial receptor expression during active labor
B) Methylergonovine is inactivated by placental enzymes and achieves insufficient myometrial concentrations during the antepartum period
C) Methylergonovine stimulates uterine contractions only through the oxytocin receptor pathway, which is not active during the first and second stages of labor
D) Methylergonovine produces sustained tonic uterine contraction with minimal relaxation intervals, which would compromise uteroplacental blood flow and cause fetal hypoxia
E) Methylergonovine causes uterine hyperstimulation only at doses above 0.4 mg, which is never used in clinical practice
ANSWER: D
Rationale:
Oxytocin produces rhythmic, phasic contractions that mimic physiological labor contractions, with relaxation intervals between contractions that maintain uteroplacental blood flow. Methylergonovine and ergometrine, in contrast, produce sustained tonic contractions with minimal or no relaxation phases, maintaining persistently elevated myometrial tone throughout the dosing interval. This tonic contraction pattern is superior for hemostasis at the placental bed after delivery but means that the spiral arteries supplying the intervillous space would be under continuous compression if ergot agents were given during active labor, causing fetal hypoxia. Labor augmentation requires phasic contractions with adequate uterine relaxation between contractions to preserve fetal oxygenation, which is precisely what ergot uterotonics do not provide.
Option A: Option A is incorrect because while progesterone maintains uterine quiescence in early and mid-pregnancy, the peripartum drop in progesterone and rise in estrogen prime the myometrium to respond to ergot alkaloids; the restriction on intrapartum use is pharmacodynamic, not a matter of receptor availability.
Option B: Option B is incorrect because methylergonovine is not inactivated by placental enzymes; it distributes to the myometrium after IM or IV administration regardless of the stage of pregnancy, and it does in fact produce myometrial contraction in the antepartum uterus — which is precisely why its intrapartum use is dangerous.
Option C: Option C is incorrect because methylergonovine does not act at oxytocin receptors directly; its uterotonic mechanism is through alpha-1 adrenergic and 5-HT2A receptor agonism.
Option E: Option E is incorrect because the tonic contraction risk is dose-independent and is present at the standard clinical dose of 0.2 mg IM; the restriction on intrapartum use applies at all doses.
3. Which physiological mechanism explains why methylergonovine produces powerful uterotonic responses in the postpartum uterus at doses that would produce negligible uterine effects in a non-pregnant woman?
A) Estrogen-mediated upregulation of alpha-1 adrenergic receptor density and 5-HT2A receptor expression in myometrial smooth muscle during pregnancy primes the term uterus for maximal ergot responsiveness
B) The postpartum uterus produces endogenous ergot-like compounds that sensitize myometrial receptors to exogenous methylergonovine
C) Methylergonovine undergoes placental bioactivation during pregnancy that converts it to a more potent uterotonic metabolite present in the postpartum period
D) Progesterone surge at term increases the number of functional alpha-1 adrenergic receptors in the myometrium, amplifying ergot-mediated calcium release
E) Uterine blood flow increases tenfold near term, accelerating methylergonovine delivery to myometrial receptors and amplifying the uterotonic response
ANSWER: A
Rationale:
The physiological state of the myometrium at the time of ergot alkaloid administration determines the magnitude and quality of the uterotonic response. Estrogen priming of the myometrium during pregnancy progressively upregulates alpha-1 adrenergic receptor density and 5-HT2A receptor expression in uterine smooth muscle, producing a state of high receptor density and high contractile sensitivity in the term myometrium. This estrogen-dependent receptor upregulation explains the striking dose-response difference between the postpartum and non-pregnant uterus and is the pharmacodynamic basis for restricting uterotonic ergot use to the postpartum or peripartum context.
Option B: Option B is incorrect because no endogenous ergot-like sensitizing compounds have been identified in the postpartum uterus; the sensitization is entirely receptor-mediated and driven by sex steroid changes.
Option C: Option C is incorrect because methylergonovine does not undergo placental bioactivation; it is metabolized primarily by hepatic CYP3A4 to lysergol, and the parent compound is the active uterotonic agent.
Option D: Option D is incorrect because the hormonal milieu at term is characterized by a dramatic decline in progesterone, not a surge; it is the peripartum drop in progesterone combined with the estrogen rise that removes the inhibitory influence on myometrial contractility and permits maximal receptor upregulation.
Option E: Option E is incorrect because while uterine blood flow does increase substantially during pregnancy, the mechanism of enhanced ergot sensitivity is pharmacodynamic (receptor density), not pharmacokinetic (delivery rate); increased blood flow would affect drug distribution but would not explain the qualitative difference in receptor responsiveness.
4. A patient receives methylergonovine maleate 0.2 mg intramuscularly immediately after delivery of the placenta. Which statement most accurately describes the expected pharmacokinetic profile of this administration route?
A) Onset of uterine contraction occurs within 45–60 seconds, with peak plasma concentrations achieved within 5 minutes due to the highly vascular postpartum uterine bed
B) Absorption is erratic and unpredictable after intramuscular injection in the postpartum state because of redistributed cardiac output away from skeletal muscle
C) Onset of uterine contraction occurs within 2–5 minutes, with peak plasma concentrations (Cmax) achieved within 20–30 minutes, reflecting absorption from the well-perfused intramuscular site
D) Onset of uterine contraction is delayed 10–15 minutes after intramuscular injection because the drug must first undergo hepatic first-pass metabolism before reaching the systemic circulation
E) Peak plasma concentrations are reached within 60–90 minutes after intramuscular injection, making the intramuscular route slower than oral sublingual administration for acute PPH control
ANSWER: C
Rationale:
After intramuscular injection, methylergonovine absorption is rapid, with onset of uterine contraction within 2–5 minutes and peak plasma concentrations (Cmax) achieved within 20–30 minutes. The absorption rate from the intramuscular site is governed by local blood flow, and the well-perfused postpartum state provides adequate circulation to produce consistently rapid and reliable uptake. This onset and peak profile makes the intramuscular route appropriate for active management of the third stage of labor, providing prompt uterotonic effect without the cardiovascular risks of the intravenous route.
Option A: Option A is incorrect because the onset of 45–60 seconds with peak at 5 minutes describes intravenous, not intramuscular, administration; intravenous dosing bypasses the absorption phase and delivers drug directly to the systemic circulation, producing a dramatically faster pharmacokinetic profile but with substantially higher cardiovascular risk.
Option B: Option B is incorrect because intramuscular absorption of methylergonovine is consistently rapid in the postpartum state; the postpartum period is characterized by high cardiac output and adequate perfusion of peripheral sites, not redistribution away from skeletal muscle.
Option D: Option D is incorrect because intramuscular injection delivers drug directly into the systemic circulation via local capillaries and avoids hepatic first-pass metabolism; first-pass metabolism applies to oral administration, not intramuscular injection.
Option E: Option E is incorrect because peak plasma concentrations after intramuscular methylergonovine occur within 20–30 minutes, not 60–90 minutes; sublingual administration provides faster onset than oral but is not faster than the well-absorbed intramuscular route in the acute postpartum setting.
5. Which set of pharmacokinetic parameters most accurately characterizes oral methylergonovine maleate as used for the extended postpartum course?
A) Oral bioavailability approximately 25–35%, elimination half-life 6–8 hours, primary metabolism by UGT glucuronidation, excretion predominantly renal
B) Oral bioavailability approximately 80–90%, elimination half-life 8–12 hours, primary metabolism by MAO oxidative deamination, excretion predominantly renal
C) Oral bioavailability approximately 15–20%, elimination half-life 1–2 hours, primary metabolism by plasma esterases, excretion equally renal and biliary
D) Oral bioavailability approximately 40–50%, elimination half-life 5–6 hours, primary metabolism by CYP2D6 hydroxylation, excretion predominantly biliary
E) Oral bioavailability approximately 60%, elimination half-life approximately 2–3.5 hours, primary metabolism by hepatic CYP3A4 hydroxylation, excretion predominantly biliary-fecal
ANSWER: E
Rationale:
Oral methylergonovine has a bioavailability of approximately 60%, substantially higher than ergotamine or ergometrine because of its lower lipophilicity and reduced susceptibility to intestinal CYP3A4 first-pass metabolism compared with more complex ergopeptine alkaloids. The elimination half-life is approximately 2–3.5 hours, which supports the three to four times daily dosing interval used for the extended oral postpartum course. Hepatic CYP3A4 mediates the primary metabolic pathway through hydroxylation, generating lysergol as the primary metabolite with modest residual pharmacological activity. Excretion is predominantly biliary and fecal, with a smaller renal component; hepatic impairment reduces clearance and may warrant dose adjustment, while renal impairment does not substantially alter methylergonovine elimination.
Option A: Option A is incorrect because the oral bioavailability of 25–35% describes ergometrine, not methylergonovine; ergometrine undergoes more extensive first-pass metabolism and has a shorter half-life, approximately 2 hours; UGT glucuronidation is not the primary metabolic route for either agent.
Option B: Option B is incorrect because an 80–90% bioavailability and 8–12 hour half-life would describe a drug with minimal first-pass metabolism and slow elimination, which does not characterize methylergonovine; MAO oxidative deamination is not a significant pathway for ergot alkaloid metabolism.
Option C: Option C is incorrect because plasma esterase metabolism and 15–20% bioavailability do not describe methylergonovine; this profile is more consistent with short-acting ester-linked drugs such as esmolol or succinylcholine.
Option D: Option D is incorrect because CYP2D6 is not the primary metabolic enzyme for methylergonovine; CYP3A4 is the dominant isoform, and the half-life of 5–6 hours substantially overestimates the elimination half-life of this drug.
6. Current ACOG guidelines specify that intravenous methylergonovine should be reserved for life-threatening hemorrhage only and should never be given as a rapid IV bolus. Which pharmacokinetic mechanism best explains the dramatically increased cardiovascular risk of intravenous compared with intramuscular administration?
A) Intravenous methylergonovine undergoes rapid plasma protein binding that redirects the drug away from the uterus and toward cardiac receptors, producing preferential cardiac toxicity
B) Intravenous administration achieves immediate peak plasma concentrations, delivering the full dose to the systemic circulation before uterine distribution occurs, producing intense peripheral vasoconstriction ahead of the uterotonic effect
C) Intravenous methylergonovine activates a different receptor subtype — the 5-HT1B receptor — that is expressed predominantly in coronary and cerebral vasculature rather than in the myometrium
D) The large volume of distribution of methylergonovine means that intravenous dosing saturates peripheral tissue compartments before the drug reaches the uterus, requiring higher doses that amplify cardiovascular toxicity
E) Intravenous methylergonovine bypasses hepatic first-pass metabolism, resulting in active metabolite accumulation that causes coronary artery vasospasm through a mechanism distinct from the parent compound
ANSWER: B
Rationale:
Intravenous administration of methylergonovine achieves immediate peak plasma concentrations, bypassing the absorption phase and delivering the full dose directly to the systemic circulation. This produces a rapid, intense peripheral vasoconstrictive response — mediated through alpha-1 adrenergic receptor and 5-HT2A receptor agonism on vascular smooth muscle — before uterine distribution can occur. Severe acute hypertension, coronary artery vasospasm, stroke, and death have been reported following IV methylergonovine, predominantly in women with pre-existing or unrecognized hypertension, pre-eclampsia, or cocaine use. When the intramuscular route is used, the gradual absorption phase allows some degree of equilibration between uterine and systemic compartments before peak concentrations are reached, substantially reducing the vasoconstrictive surge relative to the uterotonic effect.
Option A: Option A is incorrect because plasma protein binding of methylergonovine is relatively low (approximately 36%), and the mechanism of cardiovascular toxicity is not redistribution through protein binding; the drug acts on vascular smooth muscle alpha-1 ARs and 5-HT2A receptors directly, and this is not modulated by protein binding differences between routes.
Option C: Option C is incorrect because methylergonovine's cardiovascular toxicity operates through the same alpha-1 AR and 5-HT2A receptor mechanisms as its uterotonic action, not through a separate coronary 5-HT1B mechanism; the 5-HT1B receptor is relevant to the antimigraine ergotamine class, not to the uterotonic ergot alkaloids at clinical doses.
Option D: Option D is incorrect because the large volume of distribution of methylergonovine means drug distributes out of plasma into peripheral tissues, which would tend to reduce, not amplify, systemic vascular concentrations over time; the acute cardiovascular risk of IV administration is caused by the initial high plasma peak, not by tissue saturation.
Option E: Option E is incorrect because intravenous administration does bypass first-pass metabolism, but this is not the mechanism of cardiovascular toxicity; the parent compound methylergonovine is the active vasoconstrictive agent, and the primary metabolite lysergol has only modest pharmacological activity.
7. Clinicians sometimes observe that uterine tone remains elevated for 1–3 hours after intramuscular methylergonovine even though plasma concentrations decline rapidly after the peak. Which pharmacokinetic property of methylergonovine best explains this apparent discrepancy?
A) Methylergonovine undergoes enterohepatic recirculation, maintaining plasma concentrations long after the absorption phase through repeated biliary secretion and intestinal reabsorption
B) The active metabolite lysergol has a much longer plasma half-life than the parent compound and sustains uterotonic receptor activation during the post-peak period
C) Methylergonovine forms covalent bonds with myometrial alpha-1 adrenergic receptors during the initial peak exposure, creating irreversible receptor activation that persists after plasma concentrations fall
D) Methylergonovine has a large volume of distribution (approximately 39–73 L/kg) reflecting extensive tissue binding; plasma concentrations decline rapidly as drug distributes into peripheral tissues, while pharmacodynamically effective concentrations are retained in myometrial tissue
E) Sustained uterotonic activity is maintained entirely by endogenous oxytocin release triggered by ergot receptor activation, not by continued methylergonovine binding at myometrial receptors
ANSWER: D
Rationale:
Methylergonovine has a large volume of distribution (Vd) of approximately 39–73 liters per kilogram, reflecting high tissue affinity driven by its moderate lipophilicity and extensive tissue binding. Plasma protein binding is relatively low (approximately 36%), so the large Vd reflects distribution into peripheral tissues rather than plasma retention. After intramuscular dosing, plasma concentrations decline rapidly as drug distributes from plasma into peripheral compartments, giving an apparent short plasma half-life. However, pharmacodynamically effective concentrations persist at the myometrium because drug is retained in myometrial tissue at concentrations sufficient to maintain receptor activation, even while plasma concentrations fall below detectable levels. This distribution pattern explains the apparent disconnect between the short plasma half-life and the prolonged uterotonic effect of 1–3 hours after intramuscular administration.
Option A: Option A is incorrect because while methylergonovine excretion is predominantly biliary-fecal, significant enterohepatic recirculation has not been established as a mechanism maintaining plasma concentrations of this drug; the prolonged uterotonic effect is explained by tissue retention, not by recirculation maintaining plasma levels.
Option B: Option B is incorrect because lysergol, the primary CYP3A4-generated metabolite, retains only modest pharmacological activity and does not have a substantially longer plasma half-life than methylergonovine; the parent compound is responsible for the sustained uterotonic effect through tissue retention.
Option C: Option C is incorrect because methylergonovine is a partial agonist that binds reversibly to alpha-1 adrenergic and 5-HT2A receptors; it does not form covalent bonds and does not produce irreversible receptor activation; covalent receptor modification is seen with drugs like phenoxybenzamine, not ergot alkaloids.
Option E: Option E is incorrect because while oxytocin receptor cross-sensitization contributes to the overall postpartum uterotonic milieu, the sustained tonic contraction during the 1–3 hour period after methylergonovine administration is driven by continued myometrial tissue concentrations of the drug itself, not solely by endogenous oxytocin release.
8. According to current World Health Organization (WHO) recommendations for active management of the third stage of labor (AMTSL), which statement correctly describes the role of uterotonic agents in postpartum hemorrhage (PPH) prevention?
A) Oxytocin 10 IU intramuscularly is the preferred first-line uterotonic for AMTSL in all settings; ergometrine or oxytocin-ergometrine combination (Syntometrine) is listed as an acceptable alternative when oxytocin is unavailable
B) Methylergonovine 0.2 mg IM is the WHO-preferred first-line uterotonic for AMTSL because its dual receptor mechanism provides superior PPH prevention compared with oxytocin alone
C) The WHO recommends Syntometrine (oxytocin plus ergometrine) as the universal first-line combination for all AMTSL protocols because combination therapy reduces PPH incidence more than any single agent
D) The WHO does not endorse any specific uterotonic for AMTSL because the evidence base for preventing PPH in low-resource settings is insufficient to support a universal recommendation
E) Misoprostol 600 micrograms orally is the WHO-preferred first-line uterotonic for all settings, with oxytocin and ergometrine reserved for refractory cases due to injection-related infectious risks
ANSWER: A
Rationale:
The World Health Organization recommends oxytocin (10 IU intramuscularly) as the preferred first-line uterotonic for active management of the third stage of labor in all settings, based on evidence that oxytocin reduces PPH risk without the cardiovascular risks associated with ergot alkaloids. When oxytocin is unavailable, the WHO lists ergometrine or the fixed combination of oxytocin plus ergometrine — Syntometrine (5 IU oxytocin plus 0.5 mg ergometrine given intramuscularly) — as acceptable alternatives. The combination has been shown in randomized trials to reduce PPH incidence and the need for additional uterotonics compared with oxytocin alone, but at the cost of increased rates of nausea, vomiting, and hypertension from the ergometrine component, which is why it is not the universal first-line recommendation.
Option B: Option B is incorrect because methylergonovine is the ACOG-recommended ergot uterotonic in settings where oxytocin alone is insufficient, but the WHO first-line recommendation is oxytocin alone, not methylergonovine; the dual receptor mechanism of methylergonovine does not make it superior for routine AMTSL prophylaxis when weighed against its cardiovascular risks.
Option C: Option C is incorrect because Syntometrine is not the universal WHO first-line recommendation; oxytocin monotherapy is preferred as the single first-line agent, and Syntometrine is listed as an alternative rather than the universal standard because of the ergometrine-associated adverse effect profile.
Option D: Option D is incorrect because the WHO has issued explicit uterotonic recommendations for AMTSL, most recently formalized in the 2012 WHO recommendations for prevention and treatment of postpartum hemorrhage, placing oxytocin as the clear first-line choice.
Option E: Option E is incorrect because misoprostol, while heat-stable and valuable in low-resource settings lacking oxytocin refrigeration, is acknowledged by the WHO to have modestly inferior uterotonic efficacy compared with parenteral oxytocin or ergot combinations in settings where these agents are available; it is recommended as a preferred option only when oxytocin is not available, not as the universal first choice.
9. A 28-year-old woman develops postpartum hemorrhage (PPH) following an uncomplicated vaginal delivery. The obstetrics team initiates uterotonic escalation with oxytocin infusion and then adds methylergonovine 0.2 mg IM. Despite adequate uterine tone on examination, bleeding continues at a rate requiring transfusion. Which concept from the four-T framework of PPH etiology is most relevant to understanding why uterotonic escalation is failing in this patient?
A) Tone — uterine atony has not been adequately treated because methylergonovine requires 15–20 minutes to achieve full uterotonic effect after IM administration and the team should wait before escalating further
B) Thrombin — coagulopathy is the most common cause of PPH overall, and uterotonic agents are ineffective for coagulopathy-driven hemorrhage regardless of uterine tone
C) Trauma or Tissue — when the uterus is well-contracted on examination, ongoing hemorrhage is caused by a source other than atony (laceration, retained placenta, or coagulopathy), and continued uterotonic escalation will not address the actual bleeding source
D) Tone — methylergonovine should be replaced with carboprost because prostaglandin F2-alpha produces a stronger uterotonic response through a distinct receptor mechanism and the atony has simply been undertreated
E) Thrombin — all PPH cases with ongoing hemorrhage after two uterotonic agents should be presumed coagulopathic and treated empirically with fresh frozen plasma before any further diagnostic assessment
ANSWER: C
Rationale:
The four Ts of PPH etiology — Tone (uterine atony, approximately 80%), Trauma (lacerations, uterine rupture), Tissue (retained placenta or membranes), and Thrombin (coagulopathy) — determine which interventions are appropriate. Uterotonic agents including methylergonovine and oxytocin are effective only for Tone, meaning uterine atony. When clinical examination confirms adequate uterine tone — a firm, well-contracted uterus — continued uterotonic escalation will not reduce bleeding because atony is not the source. Ongoing hemorrhage in the setting of adequate uterine tone requires immediate evaluation for the other three T causes: inspection of the birth canal and uterus for lacerations or rupture (Trauma), manual or ultrasound assessment for retained placental fragments (Tissue), and coagulation testing for consumptive coagulopathy (Thrombin). Delay of these interventions by continued uterotonic escalation in this setting can be fatal.
Option A: Option A is incorrect because methylergonovine achieves onset of uterotonic effect within 2–5 minutes after IM administration; a 15–20 minute wait is not supported by pharmacokinetic data, and in the setting of confirmed adequate uterine tone, additional waiting for uterotonic effect is not clinically appropriate.
Option B: Option B is incorrect because coagulopathy (Thrombin) is not the most common cause of PPH overall — uterine atony accounts for approximately 80% of cases; while coagulopathy is an important consideration when uterotonics fail, it should be investigated rather than assumed to be present.
Option D: Option D is incorrect because the clinical question is not which uterotonic to use next but whether uterotonic escalation is the correct strategy at all; with a well-contracted uterus on examination, the bleeding is definitionally not from atony, and escalating to carboprost addresses a problem that is not present.
Option E: Option E is incorrect because empirical fresh frozen plasma without diagnostic assessment is not the recommended approach; rapid identification of PPH etiology through examination and targeted testing is the essential clinical step that directs management, and empirical plasma transfusion without evidence of coagulopathy exposes the patient to unnecessary transfusion risks.
10. A patient without hypertension or pre-eclampsia develops uterine atony following vaginal delivery. An oxytocin infusion of 40 IU in 1 liter of normal saline at 500 mL per hour has been running for 20 minutes, and bimanual uterine massage has been performed, but the uterus remains poorly contracted and bleeding continues. Which represents the most appropriate next pharmacological intervention according to stepwise PPH treatment protocol?
A) Administer carboprost tromethamine (prostaglandin F2-alpha) 250 micrograms IM as the preferred second-line uterotonic because it acts through a distinct receptor mechanism from oxytocin
B) Repeat oxytocin as a 10 IU IV bolus in addition to the ongoing infusion to achieve a higher peak plasma concentration at uterine receptors before considering additional agents
C) Administer misoprostol 800 micrograms rectally as second-line therapy because it is the only uterotonic approved for use after oxytocin failure in current ACOG guidelines
D) Discontinue oxytocin before adding a second uterotonic agent, as simultaneous use of two uterotonics is contraindicated due to risk of uterine rupture from additive myometrial stimulation
E) Administer methylergonovine 0.2 mg IM as the second-line uterotonic; its alpha-1 adrenergic and 5-HT2A receptor mechanism superimposes sustained tonic contraction on the phasic rhythm maintained by oxytocin, producing a synergistic uterotonic response
ANSWER: E
Rationale:
When an oxytocin infusion fails to achieve adequate uterine tone in the absence of contraindications, methylergonovine 0.2 mg IM is added as the second-line uterotonic in the stepwise PPH treatment protocol. The combination of oxytocin and methylergonovine is synergistic: oxytocin maintains rhythmic phasic contractions through oxytocin receptor stimulation, while methylergonovine superimposes sustained tonic contraction through alpha-1 adrenergic and 5-HT2A receptor agonism, engaging a mechanistically distinct pathway. This patient has no hypertension or pre-eclampsia, so the primary cardiovascular contraindication is absent and methylergonovine is appropriate. If this combination fails, prostaglandin F2-alpha (carboprost) or misoprostol are used as third-line agents.
Option A: Option A is incorrect because carboprost is a third-line agent, used when the combination of oxytocin plus methylergonovine has failed; it is not the preferred second-line choice. While carboprost does act through a distinct mechanism (prostaglandin F2-alpha receptors causing myometrial contraction and vasoconstriction), it carries its own contraindications including asthma and significant adverse effects that make it a step-three rather than step-two intervention.
Option B: Option B is incorrect because oxytocin IV bolus in addition to ongoing infusion risks precipitating tachyphylaxis at the oxytocin receptor; the oxytocin receptor downregulates rapidly with sustained exposure, and bolus dosing on top of continuous infusion does not reliably improve uterotonic response and may cause hypotension.
Option C: Option C is incorrect because misoprostol is used as a third-line agent when oxytocin plus methylergonovine has failed, or as an alternative when methylergonovine is contraindicated; it is not the ACOG-recommended second-line agent in the stepwise protocol for a patient without contraindications to ergot alkaloids.
Option D: Option D is incorrect because simultaneous use of oxytocin and methylergonovine is standard practice and represents the intentional synergistic combination used in stepwise PPH management; there is no contraindication to combining these agents, and discontinuing oxytocin before adding methylergonovine would remove an active uterotonic during an ongoing hemorrhage.
11. A 32-year-old primigravida with pre-eclampsia (blood pressure 148/96 mmHg at admission) delivers vaginally after labor induction. Immediately after delivery of the placenta, the obstetrician considers methylergonovine for active management of the third stage of labor. Which statement most accurately explains why methylergonovine is absolutely contraindicated in this patient?
A) Pre-eclampsia increases renal clearance of methylergonovine through glomerular hyperfiltration, causing unpredictably high peak plasma concentrations that overwhelm the uterotonic receptor capacity
B) Pre-eclampsia is associated with diffuse endothelial dysfunction, arteriolar vasospasm, and markedly increased vascular responsiveness to vasoconstrictive stimuli; methylergonovine superimposes pharmacological vasoconstrictive drive on a vasculature already operating near its pressure limits, reliably causing acute severe hypertension with risk of posterior reversible encephalopathy, intracerebral hemorrhage, and acute coronary syndrome
C) Pre-eclampsia depletes myometrial alpha-1 adrenergic receptor expression, making methylergonovine ineffective for uterotonic purposes and exposing the patient to vasoconstrictive adverse effects without any offsetting clinical benefit
D) The absolute contraindication applies only to intravenous methylergonovine in pre-eclampsia; the intramuscular route produces a slower absorption profile that allows hemodynamic monitoring and is acceptable when oxytocin is unavailable
E) Pre-eclampsia causes placental abruption in the third stage that releases tissue thromboplastin, which reacts with methylergonovine to form a toxic intermediate responsible for the reported hypertensive complications
ANSWER: B
Rationale:
Pre-eclampsia, defined by new-onset hypertension (blood pressure at or above 140/90 mmHg) with proteinuria or end-organ dysfunction at or after 20 weeks of gestation, is associated with diffuse endothelial dysfunction, arteriolar vasospasm, and markedly increased vascular responsiveness to vasoconstrictor stimuli. Methylergonovine administration in a pre-eclamptic patient superimposes pharmacological vasoconstrictive drive — through alpha-1 adrenergic and 5-HT2A receptor agonism on vascular smooth muscle — on a vasculature that is already operating near its pressure limits due to endothelial dysfunction and generalized arteriolar vasospasm. Systolic blood pressure elevations of 40–60 mmHg within 5–15 minutes of intramuscular methylergonovine have been documented in pre-eclamptic patients, with associated complications including posterior reversible encephalopathy syndrome (PRES — a neurological complication caused by failed cerebrovascular autoregulation during acute hypertension), intracerebral hemorrhage, and acute coronary syndrome. The contraindication is absolute: no uterotonic indication justifies ergot use in pre-eclampsia; oxytocin, misoprostol, or carboprost are the appropriate alternatives.
Option A: Option A is incorrect because pre-eclampsia causes reduced glomerular filtration (not hyperfiltration) from renal endothelial damage, and methylergonovine elimination is primarily hepatic-biliary rather than renal; neither mechanism explains the contraindication, which is pharmacodynamic not pharmacokinetic in origin.
Option C: Option C is incorrect because pre-eclampsia does not reduce myometrial alpha-1 AR expression; in fact, the estrogen-primed term myometrium is highly sensitized to ergot action. The contraindication is not because the drug is ineffective at the uterus but because it causes dangerous systemic vasoconstriction.
Option D: Option D is incorrect because the absolute contraindication to methylergonovine in pre-eclampsia applies to all routes of administration, including intramuscular; case series documenting acute severe hypertension following methylergonovine have involved IM administration, and the route does not eliminate the cardiovascular risk.
Option E: Option E is incorrect because no pharmacological interaction between methylergonovine and tissue thromboplastin has been described; this is not a recognized mechanism, and the hypertensive complications are explained entirely by the drug's known vasoconstrictive pharmacology acting on the pre-eclamptic vasculature.
12. A 38-year-old woman with a history of Prinzmetal angina (coronary artery vasospasm) delivers her first child via uncomplicated vaginal delivery. The attending obstetrician is planning uterotonic management for the third stage of labor. Which statement most accurately describes the appropriate uterotonic strategy for this patient?
A) Methylergonovine 0.2 mg IM is acceptable in this patient because coronary vasospasm is a relative rather than absolute contraindication, and the postpartum uterotonic benefit outweighs the vasospastic risk when given as a single intramuscular dose
B) Methylergonovine should be administered with concurrent sublingual nitroglycerin to preemptively prevent coronary vasospasm while preserving the uterotonic benefit, as this combination is endorsed by ACOG for patients with vasospastic angina
C) Carboprost (prostaglandin F2-alpha) is the preferred first-line uterotonic in this patient because it acts through prostaglandin receptors rather than adrenergic or serotonergic pathways and does not cause coronary vasoconstriction
D) Methylergonovine is absolutely contraindicated because its alpha-1 adrenergic and 5-HT2A receptor agonism causes coronary artery vasoconstriction that is not selective for the uterine vasculature; oxytocin alone should be used, with carboprost or misoprostol available as alternatives if oxytocin monotherapy fails
E) The contraindication to methylergonovine applies only to ergotamine, not to methylergonovine, because the semisynthetic modification of the ergot nucleus reduces coronary vasoconstrictive activity to clinically insignificant levels
ANSWER: D
Rationale:
Coronary artery disease and coronary artery vasospasm (Prinzmetal angina) are absolute contraindications to methylergonovine because the vasoconstrictive effect of this drug is not selective for the uterine vasculature and extends to coronary arteries through the same alpha-1 adrenergic receptor and 5-HT2A receptor agonism that produces uterotonic activity. Multiple case reports of acute myocardial infarction following methylergonovine administration exist, predominantly in women with unrecognized coronary disease, cocaine use, or ergotamine use for migraine indicating pre-existing coronary vasoreactivity. In a patient with established Prinzmetal angina — a condition defined by pathological coronary artery vasospasm — administration of a drug that pharmacologically induces coronary vasoconstriction represents an unacceptable risk. Oxytocin alone should be used for uterotonic management, with carboprost or misoprostol available as alternatives if additional uterotonic support is needed.
Option A: Option A is incorrect because the contraindication to methylergonovine in patients with coronary vasospasm is absolute, not relative; the drug's coronary vasoconstrictive mechanism operates through the same receptors responsible for its uterotonic effect and cannot be separated pharmacologically at clinical doses.
Option B: Option B is incorrect because concurrent nitroglycerin is not an endorsed strategy for enabling methylergonovine use in patients with vasospastic angina; no clinical guideline supports this combination, and the theoretical approach does not address the systemic vasoconstrictive effects beyond the coronary circulation.
Option C: Option C is incorrect because carboprost (prostaglandin F2-alpha) is a third-line uterotonic and is not the preferred first-line agent; furthermore, carboprost has its own cardiovascular effects including potential hypertension, and the correct first-line uterotonic remains oxytocin in this patient.
Option E: Option E is incorrect because the semisynthetic modification of the ergot nucleus in methylergonovine reduces uterine selectivity compared with ergometrine but does not eliminate coronary vasoconstrictive activity; case reports of myocardial infarction have been documented with methylergonovine specifically, and the contraindication applies to all uterotonic ergot alkaloids.
13. A postpartum patient is prescribed oral methylergonovine 0.2 mg four times daily for uterine subinvolution. Her current medications include clarithromycin for community-acquired pneumonia diagnosed two days postpartum. Which pharmacokinetic drug interaction is most clinically relevant in this combination?
A) Clarithromycin is a potent CYP3A4 inhibitor that reduces hepatic metabolism of methylergonovine, increasing plasma concentrations and potentially prolonging and intensifying both uterotonic and vasoconstrictive effects
B) Clarithromycin induces CYP3A4 expression, reducing methylergonovine plasma concentrations below the threshold required for uterotonic efficacy and necessitating dose doubling to maintain adequate uterine tone
C) Clarithromycin inhibits P-glycoprotein efflux at the blood-brain barrier, increasing central nervous system penetration of methylergonovine and causing ergotism-related neurological toxicity
D) Clarithromycin competes with methylergonovine for alpha-1 adrenergic receptor binding sites in myometrial smooth muscle, reducing uterotonic efficacy through pharmacodynamic antagonism
E) Clarithromycin prolongs the QTc interval, and when combined with methylergonovine — which independently shortens the QTc through adrenergic activation — the two drugs produce a paradoxical normalization of cardiac conduction with no net interaction effect
ANSWER: A
Rationale:
Methylergonovine is metabolized primarily by hepatic CYP3A4 through hydroxylation. Clarithromycin is a macrolide antibiotic and a potent inhibitor of CYP3A4, reducing the metabolic clearance of CYP3A4-substrate drugs including methylergonovine. Concurrent use of a CYP3A4 inhibitor with methylergonovine can increase methylergonovine plasma concentrations, potentially prolonging and intensifying both the uterotonic and vasoconstrictive effects of the drug. While this interaction is less acutely severe with methylergonovine than with ergotamine (where CYP3A4 inhibition can precipitate full ergotism syndrome), it is clinically relevant in a patient already taking methylergonovine at standard doses, as elevated concentrations increase cardiovascular risk. Alternative antibiotics without CYP3A4 inhibitory activity should be considered where clinically appropriate. Other drug classes sharing this interaction with methylergonovine include azole antifungals (fluconazole, itraconazole, ketoconazole) and HIV protease inhibitors (ritonavir, lopinavir).
Option B: Option B is incorrect because clarithromycin is a CYP3A4 inhibitor, not an inducer; CYP3A4 inducers (such as rifampin, carbamazepine, and St. John's wort) reduce plasma concentrations of CYP3A4 substrates by upregulating enzyme expression, but clarithromycin has the opposite effect.
Option C: Option C is incorrect because P-glycoprotein inhibition by clarithromycin, while recognized at the blood-brain barrier for some substrates, is not the clinically dominant interaction with methylergonovine; the primary pharmacokinetic concern is CYP3A4-mediated hepatic metabolism, not CNS penetration.
Option D: Option D is incorrect because clarithromycin does not bind to alpha-1 adrenergic receptors and has no pharmacodynamic activity at myometrial uterotonic receptors; this is a pharmacokinetic interaction, not a pharmacodynamic one.
Option E: Option E is incorrect because methylergonovine does not have a recognized clinically significant effect on QTc interval, and the described interaction does not reflect any established pharmacological mechanism; this combination is a confabulated distractor with no pharmacological basis.
14. During cesarean delivery under spinal anesthesia, phenylephrine infusion was used to treat spinal-induced hypotension. Immediately after delivery of the infant and placenta, the obstetrician administers methylergonovine 0.2 mg IM for uterine atony. Within five minutes, the patient's blood pressure rises acutely from 105/68 to 172/110 mmHg. Which mechanism best explains this hemodynamic response?
A) Spinal anesthesia blocks the baroreceptor reflex arc, abolishing the compensatory vasodilation that normally limits the hypertensive effect of methylergonovine during the postpartum period
B) Methylergonovine displaces phenylephrine from alpha-1 adrenergic receptor binding sites, causing a conformational change that converts the receptor to a hypersensitive state and amplifies subsequent vasoconstriction
C) Phenylephrine (a selective alpha-1 adrenergic agonist) and methylergonovine (which activates alpha-1 adrenergic receptors as part of its uterotonic mechanism) produce additive vasoconstrictive effects when administered within the same perioperative window, causing acute severe hypertension
D) The combination of phenylephrine and methylergonovine activates the renin-angiotensin system, causing angiotensin II-mediated vasoconstriction that is additive to the direct sympathomimetic effect and accounts for the delayed blood pressure rise
E) Methylergonovine inhibits the hepatic metabolism of phenylephrine by competing for CYP3A4, increasing phenylephrine plasma concentrations and prolonging its vasoconstrictive action beyond the expected duration
ANSWER: C
Rationale:
Phenylephrine is a selective alpha-1 adrenergic receptor agonist used to treat spinal anesthesia-induced hypotension during cesarean delivery. Methylergonovine activates alpha-1 adrenergic receptors as part of its uterotonic mechanism, in addition to its 5-HT2A receptor agonism. When both drugs are administered within the same perioperative window, their alpha-1 AR-mediated vasoconstrictive effects are additive: ergot-induced alpha-1 AR activation combined with phenylephrine's pure alpha-1 AR agonism can produce additive or synergistic hypertension. The blood pressure trajectory in this setting can reverse dramatically from hypotension (treated with phenylephrine) to severe hypertension (from the combined vasoconstrictive load of phenylephrine still circulating plus newly administered methylergonovine) within minutes, as occurred in this case. Communication between the obstetrician and anesthesiologist about timing of uterotonic administration relative to vasopressor use is therefore essential.
Option A: Option A is incorrect because spinal anesthesia blocks sympathetic efferent outflow and may impair some autonomic reflexes, but it does not abolish baroreceptor sensing or all central cardiovascular regulation; more importantly, the mechanism of the observed hypertension is additive direct receptor activation, not baroreceptor reflex failure.
Option B: Option B is incorrect because methylergonovine does not displace phenylephrine from alpha-1 ARs through a mechanism that creates receptor hypersensitivity; both are agonists at the same receptor, and the interaction is additive agonism, not allosteric sensitization.
Option D: Option D is incorrect because neither phenylephrine nor methylergonovine directly activates the renin-angiotensin system as a mechanism of their vasoconstrictive action; the hypertension is mediated through direct alpha-1 AR and 5-HT2A receptor activation, not through angiotensin II; furthermore, renin-angiotensin activation would produce a delayed rather than acute within-five-minute pressure rise.
Option E: Option E is incorrect because phenylephrine is not metabolized by CYP3A4; phenylephrine undergoes monoamine oxidase and sulfotransferase metabolism, and methylergonovine would not alter its plasma concentrations through a CYP3A4-competitive mechanism.
15. A patient without a known history of hypertension receives methylergonovine 0.2 mg IM for uterine atony following vaginal delivery. Eight minutes later, her blood pressure is 174/114 mmHg. She is alert but complains of a severe headache and visual changes. Which set of management steps is most consistent with current obstetric guidelines for methylergonovine-induced acute severe hypertension?
A) Administer a second dose of methylergonovine 0.2 mg IM to ensure adequate uterine tone before addressing the blood pressure elevation, then initiate antihypertensive therapy once uterine contraction is confirmed
B) Initiate magnesium sulfate infusion as first-line antihypertensive therapy for methylergonovine-induced hypertension because magnesium's vasodilatory properties are specifically effective against ergot-mediated vasoconstriction
C) Administer nitroprusside IV as first-line antihypertensive because it is the fastest-acting agent and methylergonovine-induced hypertension requires the most potent vasodilator available
D) Observe the patient for 30 minutes without pharmacological intervention because postpartum blood pressure fluctuations of this magnitude are expected and typically resolve spontaneously within one hour
E) Position the patient in left lateral decubitus; administer labetalol IV, hydralazine IV, or nifedipine oral immediate-release for blood pressure above 160/110 mmHg; do not re-administer methylergonovine; document the event as a serious adverse occurrence
ANSWER: E
Rationale:
Management of methylergonovine-induced acute severe hypertension follows the standard obstetric protocol for acute severe hypertension (systolic at or above 160 mmHg or diastolic at or above 110 mmHg). The first step is positioning the patient in left lateral decubitus to relieve aortocaval compression and optimize venous return. Pharmacological treatment is required within 30–60 minutes when blood pressure meets the acute severe threshold. The recommended agents are labetalol IV (20 mg initial dose, then 40–80 mg every 10 minutes, maximum 300 mg), hydralazine IV (5–10 mg every 20 minutes), or nifedipine oral immediate-release (10 mg, repeat in 30 minutes if needed). Methylergonovine must not be re-administered, and the event should be documented as a serious adverse occurrence. The patient's headache and visual changes are concerning for posterior reversible encephalopathy syndrome (PRES — a neurological complication caused by failed cerebrovascular autoregulation during acute severe hypertension) and require neurological assessment.
Option A: Option A is incorrect because administering a second dose of methylergonovine in this situation would directly worsen the hypertensive crisis and is absolutely contraindicated; uterine tone must be assessed without adding further vasoconstrictive load, and alternative uterotonic agents used if needed.
Option B: Option B is incorrect because magnesium sulfate is used for seizure prophylaxis in pre-eclampsia and has only modest vasodilatory effects; it is not a first-line antihypertensive for acute severe hypertension in the obstetric setting and is not specifically effective against ergot-mediated vasoconstriction; labetalol, hydralazine, or nifedipine are the guideline-recommended agents.
Option C: Option C is incorrect because nitroprusside IV is reserved for refractory hypertension when first-line agents fail; it is not the initial treatment of choice because its rapid and profound vasodilation is difficult to titrate in the acute obstetric setting, and in the postpartum context, cyanide toxicity risk remains a consideration for extended use.
Option D: Option D is incorrect because blood pressure at 174/114 mmHg with neurological symptoms (severe headache, visual changes) in the postpartum period constitutes a hypertensive emergency requiring immediate intervention; a 30-minute observation period without treatment in this presentation risks intracranial hemorrhage and is inconsistent with obstetric guidelines.
16. Clinical trials comparing Syntometrine (a fixed combination of 5 IU oxytocin plus 0.5 mg ergometrine given IM) with oxytocin alone for active management of the third stage of labor consistently show a higher rate of nausea and vomiting in the Syntometrine group, occurring in approximately 20–40% of patients. Which pharmacological property of ergometrine is primarily responsible for this adverse effect difference?
A) Ergometrine has substantially higher 5-HT2A receptor activity than oxytocin and directly activates the vomiting center in the medullary brainstem through serotonergic projections from the myenteric plexus
B) Ergometrine has prominent dopamine D2 receptor agonist activity at the chemoreceptor trigger zone, producing direct dopaminergic emetic stimulation that accounts for the nausea and vomiting associated with this drug
C) Ergometrine activates muscarinic M1 receptors in the gastrointestinal tract, increasing gastric antral contractility and causing gastroparesis-like symptoms that produce nausea and vomiting in the majority of patients
D) Ergometrine produces peripheral vasoconstriction that reduces splanchnic perfusion, causing intestinal ischemia-mediated release of serotonin from enterochromaffin cells that stimulates vagal afferents and triggers the vomiting reflex
E) Ergometrine causes acute elevation in blood pressure that stimulates baroreceptor afferents in the carotid sinus, activating the nucleus tractus solitarius and triggering nausea and vomiting as a baroreceptor-mediated reflex
ANSWER: B
Rationale:
Ergometrine has substantially higher dopamine D2 receptor activity than methylergonovine, and dopamine D2 receptor agonism at the chemoreceptor trigger zone (CTZ — a specialized area in the area postrema at the floor of the fourth ventricle that lies outside the blood-brain barrier and samples blood for emetic stimuli) is the primary mechanism of ergot-induced nausea and vomiting. This emetic potency is the primary reason for the prominent nausea and vomiting that accompany Syntometrine, producing vomiting in approximately 20–40% of patients compared with less than 10% with oxytocin alone. The higher D2 receptor activity of ergometrine relative to methylergonovine is the pharmacological basis for preferring methylergonovine when an ergot uterotonic is required, and is a key consideration in the decision to list Syntometrine as an alternative rather than the universal first-line combination for AMTSL.
Option A: Option A is incorrect because while ergometrine has 5-HT2A receptor activity that contributes to its uterotonic and vasoconstrictive actions, the emetic effect is mediated primarily through dopamine D2 receptor agonism at the CTZ, not through direct 5-HT2A activation of the medullary vomiting center; the two receptor systems serve different pharmacological functions for this drug.
Option C: Option C is incorrect because ergometrine does not have significant muscarinic M1 receptor activity and does not cause gastroparesis through a cholinergic mechanism; the ergot alkaloids are not clinically significant muscarinic agonists, and the emetic mechanism is dopaminergic at the CTZ, not peripheral cholinergic.
Option D: Option D is incorrect because while ergometrine does cause splanchnic vasoconstriction, ischemia-mediated serotonin release from enterochromaffin cells is not the established mechanism of ergot-induced emesis; this pathway is relevant to cytotoxic chemotherapy-induced nausea but not to ergot pharmacology.
Option E: Option E is incorrect because while methylergonovine does cause blood pressure elevation that activates baroreceptors, baroreceptor-mediated nausea is not the established mechanism of ergot-induced emesis; the dopamine D2 receptor pathway at the CTZ is the primary mechanism, and this is independent of the blood pressure effects.
17. Which comparison of the pharmacokinetic properties of ergometrine and methylergonovine is most accurate, and what is the clinical implication of the stated difference?
A) Ergometrine has oral bioavailability of approximately 70–80%, substantially higher than methylergonovine at approximately 60%, making ergometrine the preferred agent for extended oral postpartum treatment because fewer tablets are needed to achieve equivalent plasma exposure
B) Ergometrine has a longer elimination half-life of approximately 6–8 hours compared with methylergonovine at 2–3.5 hours, allowing once-daily oral dosing for ergometrine versus three to four times daily dosing required for methylergonovine
C) The two agents have nearly identical bioavailability (both approximately 60%) and half-lives (both approximately 2.5 hours), and clinical preference for methylergonovine over ergometrine is based entirely on lower cost rather than any pharmacokinetic difference
D) Ergometrine has lower oral bioavailability (approximately 25–47%) than methylergonovine (approximately 60%) due to greater first-pass hepatic metabolism; its elimination half-life of approximately 2 hours is slightly shorter than methylergonovine's 2–3.5 hours, requiring more frequent dosing for an extended oral postpartum course
E) Ergometrine achieves higher peak plasma concentrations than methylergonovine after equivalent intramuscular doses because ergometrine has a substantially smaller volume of distribution, confining more of the absorbed dose to the plasma compartment and amplifying peak receptor exposure
ANSWER: D
Rationale:
Ergometrine has lower oral bioavailability than methylergonovine — approximately 25–47% versus approximately 60% for methylergonovine — reflecting its greater susceptibility to intestinal and hepatic first-pass CYP3A4 metabolism. This lower bioavailability is one pharmacokinetic factor that makes methylergonovine the preferred ergot alkaloid for the extended oral postpartum course. The elimination half-life of ergometrine is approximately 2 hours, slightly shorter than methylergonovine's 2–3.5 hours, which would require more frequent dosing to maintain adequate plasma concentrations for sustained uterotonic effect during the postpartum period. In practice, the pharmacokinetic differences between the two agents are clinically secondary to their pharmacodynamic similarities; the clinical preference for methylergonovine over ergometrine is driven primarily by its lower emetic activity (less dopamine D2 receptor activity), similar cardiovascular contraindication profile with somewhat better tolerability, and more favorable storage requirements, rather than by the modest pharmacokinetic differences alone.
Option A: Option A is incorrect because ergometrine has lower oral bioavailability than methylergonovine, not higher; an oral bioavailability of 70–80% substantially overestimates ergometrine's absorption and incorrectly reverses the comparison between the two agents.
Option B: Option B is incorrect because ergometrine has a shorter, not longer, elimination half-life than methylergonovine; a half-life of 6–8 hours for ergometrine does not correspond to its established pharmacokinetic profile, and once-daily dosing is not appropriate for either agent given their half-lives in the 2–3.5 hour range.
Option C: Option C is incorrect because the two agents do not have nearly identical bioavailability; methylergonovine's approximately 60% oral bioavailability is substantially higher than ergometrine's approximately 25–47%, and clinical preference for methylergonovine is driven by pharmacological and pharmacokinetic differences, not primarily by cost.
Option E: Option E is incorrect because while ergometrine may have a somewhat smaller volume of distribution than methylergonovine, the comparison of peak plasma concentrations after equivalent intramuscular doses and the clinical implications stated are not supported by the established pharmacokinetic literature; peak plasma concentrations after intramuscular ergometrine occur slightly faster (2–3 minutes) rather than higher than methylergonovine, reflecting absorption rate rather than volume of distribution differences.
18. A global health organization is evaluating uterotonic protocols for PPH prevention in remote primary care facilities in sub-Saharan Africa where reliable cold-chain supply and refrigeration cannot be guaranteed. Which pharmacological property most directly supports selecting misoprostol over ergometrine for this setting?
A) Ergometrine requires refrigerated storage at 2–8 degrees Celsius and degrades rapidly at ambient temperatures, making it unreliable in facilities without a consistent cold chain; misoprostol is heat-stable at ambient temperatures and can be stored and distributed without refrigeration
B) Ergometrine is associated with a higher rate of failed uterine contraction than misoprostol in low-resource settings because nutritional deficiencies common in these populations reduce myometrial receptor expression and impair ergot uterotonic efficacy
C) Misoprostol is a parenteral agent that can be administered more reliably than ergometrine in community settings because it does not require trained injection technique or sterile equipment
D) Ergometrine has a shorter duration of action (approximately 15–20 minutes) compared with misoprostol (4–6 hours), making it unsuitable for resource-limited settings where repeat dosing is not feasible
E) Misoprostol's higher affinity for uterine oxytocin receptors compared with ergometrine's alpha-1 adrenergic mechanism makes it more effective at preventing atony in the term postpartum uterus independent of storage conditions
ANSWER: A
Rationale:
Ergometrine is substantially more heat-labile than methylergonovine and requires refrigerated storage at 2–8 degrees Celsius to maintain potency; degradation at ambient tropical temperatures renders the drug ineffective, and unreliable cold-chain supply is a critical practical limitation for ergometrine use in low-resource settings. Misoprostol, a synthetic prostaglandin E1 analog available as an oral tablet, is heat-stable at ambient temperatures and can be stored and distributed without refrigeration, making it the preferred uterotonic for AMTSL in settings where cold-chain supply chains are unreliable. The WHO has endorsed misoprostol as the preferred uterotonic for community-level and low-resource PPH prevention on this basis, despite its modestly inferior uterotonic efficacy compared with parenteral oxytocin or ergot combinations in high-resource settings where cold-chain storage is reliable.
Option B: Option B is incorrect because the selection of misoprostol over ergometrine in low-resource settings is driven by storage and logistics considerations, not by nutritional effects on myometrial receptor expression; nutritional status does not substantially alter alpha-1 adrenergic or prostaglandin receptor density in a clinically meaningful way that would shift agent selection.
Option C: Option C is incorrect because misoprostol is not a parenteral agent; it is administered orally, sublingually, or rectally, which are indeed advantages over injection-based uterotonics in community settings, but misoprostol's primary practical advantage in this context is its heat stability, not its non-injectable nature, and the question specifically asks about the property most relevant to cold-chain limitations.
Option D: Option D is incorrect because ergometrine does not have a duration of action of only 15–20 minutes; its uterotonic effect persists for 1–2 hours after intramuscular administration, similar to methylergonovine. Misoprostol's duration of action is longer but the stated comparison values are inaccurate, and duration of action is not the primary reason ergometrine is unsuitable for this setting.
Option E: Option E is incorrect because misoprostol acts on prostaglandin E receptors (EP2/EP3 subtypes), not on oxytocin receptors; it does not have higher affinity for oxytocin receptors than ergometrine, and the claim of superior efficacy through oxytocin receptor affinity is pharmacologically incorrect.
19. A patient with severe persistent asthma controlled on inhaled budesonide and salmeterol delivers vaginally and develops refractory uterine atony that has not responded to oxytocin infusion and methylergonovine 0.2 mg IM. The team is considering third-line uterotonic options. Which statement most accurately guides the choice of additional uterotonic therapy in this patient?
A) Carboprost tromethamine (prostaglandin F2-alpha, Hemabate) 250 micrograms IM is the preferred third-line agent because its prostaglandin mechanism is the most potent available and asthma is only a relative contraindication that can be managed with concurrent bronchodilator pretreatment
B) Ergometrine 0.5 mg IM can be used as third-line therapy in this patient because she has already received methylergonovine, and switching to the parent ergot compound accesses a slightly different receptor affinity profile that may overcome the methylergonovine resistance
C) Carboprost is absolutely contraindicated in this patient because prostaglandin F2-alpha causes bronchoconstriction and can precipitate life-threatening bronchospasm in patients with asthma; misoprostol (prostaglandin E1) 800–1,000 micrograms rectally or sublingually is the appropriate third-line alternative
D) All prostaglandin-based uterotonics including both carboprost and misoprostol are absolutely contraindicated in asthma, and the only option remaining after methylergonovine failure in this patient is surgical uterine compression sutures or hysterectomy
E) Carboprost can be administered safely in this patient if the maximum single dose is reduced from 250 micrograms to 125 micrograms and the dosing interval is extended from 15 minutes to 30 minutes, as the bronchoconstriction risk is dose-dependent and eliminated at lower doses
ANSWER: C
Rationale:
Carboprost tromethamine is a synthetic analog of prostaglandin F2-alpha and causes smooth muscle contraction through prostaglandin F receptors (FP receptors). Prostaglandin F2-alpha contracts bronchial smooth muscle, and carboprost is absolutely contraindicated in patients with asthma because it can precipitate severe, life-threatening bronchospasm. This contraindication is not mitigated by bronchodilator pretreatment and applies regardless of asthma severity. In contrast, misoprostol is a prostaglandin E1 analog that acts on EP2 and EP3 receptor subtypes; EP2 receptor activation produces bronchodilation (the same mechanism as beta-2 adrenergic agonists via cAMP elevation), and misoprostol does not cause bronchoconstriction. Misoprostol 800–1,000 micrograms rectally or sublingually is therefore the appropriate third-line uterotonic in a patient with asthma for whom carboprost is contraindicated, providing prostaglandin-mediated uterotonic activity through a receptor subtype that is safe in the setting of reactive airway disease.
Option A: Option A is incorrect because asthma is an absolute contraindication to carboprost, not a relative one; bronchodilator pretreatment does not adequately prevent carboprost-induced bronchospasm in asthmatic patients, and this approach is not endorsed by obstetric guidelines.
Option B: Option B is incorrect because ergometrine and methylergonovine share the same receptor mechanism (alpha-1 AR and 5-HT2A agonism) and the same cardiovascular contraindication profile; switching from methylergonovine to ergometrine does not access a meaningfully different receptor spectrum that would overcome resistance, and in a patient who has already received methylergonovine, escalation should proceed to a different drug class.
Option D: Option D is incorrect because while carboprost is absolutely contraindicated in asthma, misoprostol (prostaglandin E1) is not contraindicated and does not cause bronchoconstriction; surgical options are considered when all appropriate pharmacological options have been exhausted, but misoprostol remains available and should be used before escalating to surgical management.
Option E: Option E is incorrect because the bronchoconstriction risk of carboprost is not reliably dose-dependent in a way that permits safe use at reduced doses in asthmatic patients; the absolute contraindication applies regardless of dose modification, and no dose reduction protocol has established safety of carboprost in asthma.
20. A randomized controlled trial comparing Syntometrine (5 IU oxytocin plus 0.5 mg ergometrine IM) with oxytocin 10 IU IM alone for active management of the third stage of labor reports that the Syntometrine group had a statistically significantly lower rate of postpartum hemorrhage exceeding 500 mL, but also significantly higher rates of nausea, vomiting, and hypertension. Which statement best explains the pharmacological basis for this trade-off?
A) Syntometrine's superior PPH prevention is due entirely to the oxytocin component; ergometrine contributes only adverse effects and no additional uterotonic benefit beyond what oxytocin provides alone
B) The nausea and vomiting observed with Syntometrine are caused by the oxytocin component because high-dose oxytocin activates V2 vasopressin receptors in the hypothalamus, triggering a neuroendocrine emetic response that does not occur at lower doses
C) Syntometrine causes hypertension through a pharmacodynamic interaction in which oxytocin upregulates vascular alpha-1 adrenergic receptors, amplifying the vasoconstrictive potency of the ergometrine component beyond what ergometrine alone would produce
D) The adverse effects of Syntometrine are caused solely by the ergometrine component because oxytocin alone at 5 IU produces no uterotonic activity; the 5 IU oxytocin dose in Syntometrine is pharmacologically inert and serves only as a pharmaceutical excipient
E) Syntometrine's combination provides superior PPH prevention because ergometrine's alpha-1 adrenergic and 5-HT2A-mediated tonic contraction is additive with oxytocin's phasic contractile mechanism, but the ergometrine component is responsible for the higher rates of nausea (dopamine D2 CTZ activation), vomiting, and hypertension (systemic vasoconstriction) observed in the ergometrine group
ANSWER: E
Rationale:
Syntometrine combines 5 IU oxytocin with 0.5 mg ergometrine in a single intramuscular injection. The superior PPH prevention observed with Syntometrine compared with oxytocin alone reflects the additive uterotonic mechanisms: oxytocin produces rhythmic phasic myometrial contractions through oxytocin receptors (Gq-coupled, IP3-mediated calcium release), while ergometrine superimposes sustained tonic contraction through alpha-1 adrenergic receptor and 5-HT2A serotonin receptor agonism — a mechanistically distinct pathway. The combination thus engages three receptor systems simultaneously, producing a more complete and sustained uterotonic response than either agent alone. The adverse effects — nausea and vomiting in 20–40% of patients, and hypertension — are attributable to the ergometrine component: nausea and vomiting arise from ergometrine's dopamine D2 receptor agonism at the chemoreceptor trigger zone (CTZ), and hypertension arises from ergometrine's alpha-1 AR and 5-HT2A-mediated vasoconstriction of systemic vascular smooth muscle. This is the pharmacological reason why the WHO recommends oxytocin monotherapy as first-line rather than the more efficacious Syntometrine combination.
Option A: Option A is incorrect because ergometrine does contribute meaningfully to the uterotonic efficacy of Syntometrine through its dual alpha-1 AR and 5-HT2A mechanism; the combination's superiority over oxytocin alone reflects additive activity across mechanistically distinct receptor systems, not just oxytocin activity.
Option B: Option B is incorrect because oxytocin's adverse effect profile at standard doses does not include nausea through V2 receptor activation; at high doses oxytocin can cause antidiuretic effects through V2-like cross-reactivity, but nausea and vomiting in the Syntometrine comparison trials are attributable to the ergometrine component.
Option C: Option C is incorrect because oxytocin does not upregulate vascular alpha-1 adrenergic receptors; the hypertension observed with Syntometrine is a direct pharmacodynamic effect of ergometrine's vasoconstrictive receptor activity, not an oxytocin-mediated amplification of ergometrine potency.
Option D: Option D is incorrect because 5 IU oxytocin is a full standard dose for AMTSL and is pharmacologically active; 10 IU IM is the standard monotherapy dose, but 5 IU is not pharmacologically inert and contributes meaningfully to the uterotonic effect of Syntometrine through oxytocin receptor activation.
21. The WHO's current guidelines place oxytocin as the sole first-line uterotonic for active management of the third stage of labor, limiting ergot alkaloids to second-line or alternative status. Which statement most accurately reflects the WHO's pharmacological rationale for this position?
A) Ergot alkaloids have been shown in head-to-head trials to be less effective than oxytocin at preventing PPH in all settings, making their continued use pharmacologically unjustifiable regardless of cardiovascular risk considerations
B) The cardiovascular risks of ergot alkaloids — including acute severe hypertension, coronary artery vasospasm, and stroke — are unacceptable as a routine prophylactic measure in the general obstetric population given that oxytocin provides equivalent or superior PPH prevention without those risks; ergot uterotonics retain value as second-line agents when oxytocin alone fails and as combination therapy in high-risk settings
C) Ergot alkaloids are no longer recommended in any capacity by the WHO, having been replaced entirely by misoprostol in all settings based on heat stability and safety profile
D) The WHO restriction on ergot alkaloids applies specifically to the intravenous route; intramuscular ergometrine remains WHO-endorsed as a first-line alternative to oxytocin in all settings, including those where oxytocin is available
E) The restriction on ergot alkaloids reflects concern about teratogenicity in women who are unknowingly pregnant at the time of AMTSL administration, rather than cardiovascular risk in the woman receiving the drug
ANSWER: B
Rationale:
The WHO's assessed position is that the cardiovascular risks of ergot alkaloids — acute severe hypertension, coronary artery vasospasm, myocardial infarction, and stroke arising from alpha-1 adrenergic and 5-HT2A receptor-mediated systemic vasoconstriction — are unacceptable as a routine prophylactic measure in the general obstetric population, given that oxytocin provides equivalent or superior PPH prevention without those risks. This is a risk-benefit judgment at the population level: the absolute PPH prevention benefit of adding ergot to routine AMTSL does not justify exposing all delivering women to the cardiovascular risks when a safer alternative of equivalent efficacy exists. Ergot uterotonics retain clinical value as second-line agents for atonic PPH refractory to oxytocin, and in Syntometrine combination when additional uterotonic potency is specifically required. The pharmacology of ergot uterotonics is considered precisely targeted and mechanistically valuable, but their routine prophylactic use has appropriately yielded to agents with safer cardiovascular profiles for universal application.
Option A: Option A is incorrect because the head-to-head trial evidence does not uniformly show ergot alkaloids to be less effective than oxytocin; in many comparisons, ergot-containing combinations (particularly Syntometrine) reduce PPH incidence more than oxytocin alone; the WHO's restriction is primarily based on safety, not inferior efficacy.
Option C: Option C is incorrect because the WHO has not removed ergot alkaloids from all recommendations; ergometrine and Syntometrine remain listed as acceptable alternatives when oxytocin is unavailable, and ergot agents retain a second-line role in treatment protocols; misoprostol is preferred in specific low-resource contexts for practical logistics reasons, not because ergot has been eliminated from guidelines.
Option D: Option D is incorrect because the WHO restriction on ergot alkaloids as first-line AMTSL agents applies to all routes, not just intravenous administration; intramuscular ergometrine is not WHO-endorsed as a first-line alternative when oxytocin is available.
Option E: Option E is incorrect because the WHO guideline restriction on ergot alkaloids is based on cardiovascular risk in the patient receiving the drug, not on teratogenicity concerns; ergot alkaloids are administered postpartum or immediately peripartum when teratogenic risk to a new pregnancy is not the relevant consideration.
22. Before administering methylergonovine or ergometrine for postpartum hemorrhage management, a clinician should confirm a set of safety criteria. Which combination of pre-administration checks is most consistent with the required safety checklist for uterotonic ergot alkaloids?
A) Confirm the patient is not breastfeeding; verify serum potassium is above 3.5 mEq/L; confirm no history of latex allergy; verify intramuscular injection site has no local infection; and confirm the drug has not been stored above 25 degrees Celsius
B) Confirm urine output is above 30 mL per hour; verify hemoglobin is above 8 g/dL; confirm no history of hepatic cirrhosis; verify no concurrent SSRI use; and confirm gestational age is at least 37 weeks at the time of delivery
C) Confirm no concurrent use of tocolytic agents; verify maternal temperature is below 38 degrees Celsius; confirm no history of allergy to penicillin; verify blood type and crossmatch are completed; and confirm vaginal delivery rather than cesarean was performed
D) Confirm blood pressure is below 140/90 mmHg measured within the preceding 30 minutes; confirm no history of hypertension, pre-eclampsia, coronary artery disease, peripheral vascular disease, or vasospastic conditions; confirm no cocaine use; confirm no concurrent potent CYP3A4 inhibitors or vasopressor administration; and confirm route is intramuscular unless life-threatening hemorrhage with continuous blood pressure monitoring
E) Confirm no concurrent use of oxytocin infusion, as simultaneous use of oxytocin and methylergonovine is contraindicated due to risk of uterine rupture; verify platelet count is above 100,000 per microliter; confirm no prior exposure to ergot alkaloids in the current pregnancy; and confirm the patient has not received epidural analgesia within the preceding two hours
ANSWER: D
Rationale:
The required safety checklist before administering any uterotonic ergot alkaloid — methylergonovine or ergometrine — addresses the specific contraindication profile of this drug class. The checklist should confirm: blood pressure measured within the preceding 30 minutes is below 140/90 mmHg (the threshold defining hypertension); no history of hypertension, pre-eclampsia, or gestational hypertension in the current or prior pregnancy; no history of coronary artery disease, myocardial infarction, peripheral vascular disease, or vasospastic conditions including Prinzmetal angina; no cocaine use (which sensitizes vascular alpha-1 adrenergic and serotonin receptors to ergot-induced vasospasm); no concurrent use of potent CYP3A4 inhibitors (macrolide antibiotics, azole antifungals, HIV protease inhibitors) or vasopressors (phenylephrine, ephedrine) within the preceding 15 minutes; and confirmation that the route is intramuscular rather than intravenous unless the hemorrhage is life-threatening and continuous blood pressure monitoring is available. Emergency antihypertensive agents should be confirmed available at the bedside in any patient with borderline blood pressure readings before administration proceeds.
Option A: Option A is incorrect because breastfeeding status, serum potassium, latex allergy, injection site assessment, and storage temperature — while potentially relevant to general medication administration — are not the specific cardiovascular safety criteria that define the ergot alkaloid safety checklist; the dominant risks are cardiovascular, and the checklist targets them directly.
Option B: Option B is incorrect because urine output, hemoglobin, hepatic function, SSRI use, and gestational age are not the specific contraindication criteria for uterotonic ergot alkaloids; while hepatic impairment does affect methylergonovine clearance, it is not among the acute safety checklist items, and SSRI use is not a contraindication to ergot uterotonics in the obstetric context.
Option C: Option C is incorrect because tocolytic use, maternal temperature, penicillin allergy, blood type, and delivery route are not the specific pre-administration safety criteria for uterotonic ergot alkaloids; the checklist is entirely oriented toward cardiovascular and drug interaction contraindications.
Option E: Option E is incorrect because simultaneous use of oxytocin and methylergonovine is standard clinical practice representing the intended synergistic combination — it is not contraindicated and does not risk uterine rupture; platelet count, prior ergot exposure, and epidural timing are not components of the established ergot safety checklist.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.